SCHEMBL2004452

SCHEMBL2004452

Clc1cc(Cl)cc(Nc2nc3ccccc3[nH]2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
NPC1 O15118 6/20 0.55
RAB9A P51151 6/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
MAPT P10636 2/20 0.55
AKR1C3 P42330 1/20 0.55
ALOX15 P16050 2/20 0.53
GAA P10253 1/20 0.53
ALDH1A1 P00352 1/20 0.53
HPGD P15428 1/20 0.53
DDX3X O00571 1/20 0.52
GFER P55789 1/20 0.51
NPSR1 Q6W5P4 2/20 0.50
NOD1 Q9Y239 1/20 0.50
KCNH2 Q12809 1/20 0.50
PDE10A Q9Y233 1/20 0.49
CYP1A2 P05177 1/20 0.49
LMNA P02545 1/20 0.49
TP53 P04637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1999901 0.88 AKR1C3 (0.63) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL1163897 0.85 MEN1 (0.71) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL1999899 0.81 MEN1 (0.61) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL239690 0.81 MEN1 (0.75) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL30020996 0.81 MEN1 (0.75) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL2002403 0.81 MEN1 (0.57) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL1996492 0.81 MEN1 (0.60) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL28050241 0.80 RAB9A (0.68) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL30289873 0.79 KDM4E (0.71) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL28728369 0.79 RAB9A (0.66) MEN1KMT2ANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960561-B2 2-(phenylamino) benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels NEUROSEARCH A/S (DK) 2011-06-14 US claimed
US-20090076106-A1 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels NEUROSEARCH A/S (DK) 2009-03-19 US claimed
US-7960561-B2 2-(phenylamino) benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels NEUROSEARCH A/S (DK) 2011-06-14 US disclosed
US-20090076106-A1 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels NEUROSEARCH A/S (DK) 2009-03-19 US disclosed
EP-1896427-A2 NOVEL 2-(PHENYLAMINO)BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS NeuroSearch A/S (DK) 2008-03-12 EP disclosed
WO-2006136580-A2 2-(PHENYLAMINO)BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076106-A1 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels KCNN2, KCNN1, KCNN3 MEN1 2186/4885KMT2A 1406/4885NPC1 1565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.